- AuthorisedTherapeutic exploratory (Phase II)
Antisense Oligonucleotide Eye Drops Against IRS-1 to Treat Pathological Corneal Neovascularisation in Aniridia-Associated Keratopathy (Olisens-Aniridia)
This study is testing new eye drops called OLISENS for people with a rare eye condition called aniridia, which can cause new blood vessels to grow on the clear front part of the eye (cornea). The drops aim to reduce these unusual blood vessels.
For: Corneal Neovascularization in Aniridia-associated KeratopathyGermany - AuthorisedTherapeutic exploratory (Phase II)
Antisense Oligonucleotide Eye Drops against IRS-1 to Optimize Pretransplant Lymphangio-regression Prior to High-Risk Keratoplasty (Olisens-Precon)
This study is testing new eye drops called OLISENS for adults with specific eye damage before a high-risk cornea transplant. The aim is to reduce abnormal blood vessels in the eye, which may improve transplant success. It's a phase II trial to check safety and how well it works.
For: Pathologically prevascularized corneas due to herpetic keratopathy prior to “high-risk” corneal transplantation (keratoplasty)Germany